• Eledon flagged new patient-reported outcomes from its Phase 2 BESTOW kidney-transplant trial of tegoprubart versus tacrolimus.
• Results have not been presented yet; an oral presentation is scheduled for Oct. 23, 2026, at ASN Kidney Week in Denver.
• The update focuses on how patients reported their experience on tegoprubart compared with standard tacrolimus-based care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839924) on October 05, 2026, and is solely responsible for the information contained therein.